Hystrogest

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hystrogest

What is Hystrogest?

Hystrogest is a pharmaceutical formulation containing dydrogesterone, a synthetic progestogen that is orally active. It is designed to act similarly to the natural female hormone, progesterone, by interacting with specific receptors in the body. Unlike some other synthetic hormones, dydrogesterone is chemically related to natural progesterone, which influences its profile of activity and how it is processed by the body.

Mechanism of Action

The primary function of Hystrogest is to supplement or replace progesterone in instances where the body does not produce sufficient levels of the hormone. It works by acting directly on the lining of the uterus (the endometrium). In a typical hormonal cycle, progesterone is responsible for preparing and maintaining the uterine lining. By providing a stable progestogenic effect, Hystrogest helps to regulate the growth and shedding of the endometrium.

Therapeutic Use

Hystrogest is utilized in various clinical scenarios related to hormonal imbalances. Its applications generally fall into two categories:

  • Hormone Replacement Therapy (HRT): When used alongside estrogen therapy, it helps protect the lining of the uterus from overgrowth, which can occur if estrogen is used alone.
  • Gynecological Conditions: It is used to manage conditions where progesterone deficiency plays a role, such as irregular menstrual cycles, certain types of abdominal pain or bleeding associated with the cycle, and support for the uterine environment in specific reproductive contexts.

Because it does not interfere with the body's natural process of ovulation at standard therapeutic doses, it is often selected for conditions where maintaining the physiological cycle is beneficial.

What side effects are possible with Hystrogest?

Possible Side Effects and Safety Information

This information describes the possible side effects and safety restrictions for Hystrogest, as documented in official government regulatory documents.

Safety Restrictions (Contraindications)

Official regulatory labeling establishes that Hystrogest must not be used if a person has certain pre-existing conditions. These absolute restrictions include a history of or active arterial or venous thromboembolic disorders (such as deep vein thrombosis or pulmonary embolism), known or suspected breast cancer or other hormone-sensitive cancers, undiagnosed abnormal genital bleeding, or active liver disease.

Adverse Reactions and Frequency

Regulatory documents detail adverse reactions based on their frequency observed in clinical studies and post-marketing reports.

Classification Examples of Documented Adverse Reactions
Common (Reported ge 5%) Injection site pain and swelling, urticaria (hives or rash).
Serious (Rare) Pulmonary embolism, injection site cellulitis.

Clinical Safety Warnings and Monitoring

Certain physiological changes require careful monitoring during the use of this medicine as defined in the official regulatory warnings and precautions section:

  • Cardiovascular and Metabolic: Patients should be monitored for the development of hypertension (high blood pressure) and jaundice. There is a documented risk of a decrease in glucose tolerance, which is relevant for diabetic or prediabetic patients.
  • Fluid Balance: Due to the risk of fluid retention, close monitoring is required for patients with preeclampsia, epilepsy, or existing cardiac or renal dysfunction.

Emerging Safety Data

Regulatory bodies have reviewed data concerning the medicine's long-term safety, including an emerging signal suggesting a possible increased risk of cancer in people who were exposed to the drug in the womb (in utero). This has led to action, including the suspension of marketing authorizations in some regulatory regions.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information for Hystrogest

Element Regulatory Statement or Documented Finding
Documented overdose presentations Exposure to excessive amounts of Hystrogest is primarily documented to present with signs of central nervous system and mild gastrointestinal disturbance.
Physiological systems affected (as stated in label) The principal systems involved include the Central Nervous System (resulting in somnolence, drowsiness, dizziness, or euphoria) and the Gastrointestinal System (leading to nausea and vomiting).
Emergency-response statements (as written in official documents) Symptomatic and supportive treatment are the officially described management procedures. It is stated that no specific antidote is known for Progesterone overdose.
When immediate medical help is required (label-derived phrasing only) Seek immediate medical attention upon the suspicion of an overdose event; hospital monitoring for observation of symptoms may be required.

Overdose Classifications (High-Level)

Classification Regulatory Statement
Severity classification (as defined in official documents) The regulatory classification often notes that overdose of this agent is generally not life-threatening.
Population-specific overdose notes (if applicable) No specific data detailing differences in overdose severity for pediatric, geriatric, or renally/hepatically impaired populations is explicitly provided in standard regulatory overdose sections.

Official Overdose Statements

  • The overdose clinical presentation is commonly documented as CNS-related effects like somnolence.
  • The mandatory response is to secure urgent medical care.
  • Management is limited to supportive measures, as no known antidote exists.

Connection to the overall overdose profile (2–4 sentences): Official regulatory documents define the overdose profile by its documented clinical signs, which are primarily related to reversible central nervous system effects. This characterization dictates the required emergency-seeking condition: immediate medical evaluation must be secured for the provision of appropriate symptomatic and supportive care, as explicitly stated in the regulatory labeling.

Therapeutic Uses of Hystrogest

What Hystrogest Treats: Main Uses and Benefits

This medication may assist with managing core symptoms related to systemic imbalance that can be associated with hormonal fluctuations. It is commonly used across conditions presenting with episodic or fluctuating manifestations, such as irregular menstrual cycles, abnormal uterine bleeding, and symptoms associated with the transition to menopause.

This medicine is relevant for easing menopausal symptoms (like hot flashes) and plays a role in managing the health of the uterine lining in women taking estrogens.

It is also applied in settings that involve temporary physiological imbalance, specifically in the context of assisted reproductive technology (ART). In these scenarios, it provides supportive hormonal assistance, which may assist with providing supportive conditions in the early stages of pregnancy.

“This therapy is applied across domains where additional symptomatic support is needed.”

This overall approach supports the patient during difficult episodes by contributing to easing the overall symptom load and assisting with maintaining functional stability.

Quick Fact: Symptomatic support for Hot Flashes (This medicine, when part of combined therapy, is commonly used to help with vasomotor symptoms.)

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Hystrogest (micronized progesterone) is generally prescribed to address conditions linked to progesterone deficiency or to provide progestogen support during hormone replacement therapy (HRT) in women with an intact uterus. It is frequently used for issues such as menstrual irregularities, premenstrual syndrome, benign breast conditions, and as a supplement during fertility treatments, including in vitro fertilization (IVF).

However, Hystrogest is contraindicated and should not be used in several circumstances. Patients must inform their healthcare provider of their full medical history. The following table summarizes key exclusion criteria:

Condition Reason for Caution/Exclusion
Allergy Known hypersensitivity to progesterone or any component of the formulation.
Cancer Current or suspected hormone-sensitive cancer, such as breast or uterine cancer.
Vascular Issues Active or history of thromboembolic disorders (blood clots), including deep vein thrombosis, pulmonary embolism, stroke, or heart attack.
Liver Disease Severe liver disease or impaired liver function.
Bleeding Undiagnosed or abnormal vaginal bleeding.

Additional caution is advised for patients with conditions that can be worsened by fluid retention, such as asthma, epilepsy, migraine, heart disease, or kidney impairment. Patients with a history of depression or diabetes require careful monitoring. Always consult a healthcare professional to determine if Hystrogest is appropriate for your specific health situation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Hystrogest (hydroxyprogesterone caproate) is primarily metabolized by the cytochrome P450 (CYP) enzyme system, particularly the CYP3A4 and CYP3A5 pathways. Medications that significantly affect these enzymes can alter the concentration of Hystrogest in the bloodstream, potentially leading to a loss of therapeutic effect or an increase in side effects.

Documented Interaction Categories

Category Mechanism & Effect
Enzyme Inducers Potent inducers of CYP450 enzymes (such as Rifampin, Griseofulvin, Nevirapine, Phenytoin, and Carbamazepine) can increase the breakdown of Hystrogest, leading to lower plasma levels. This is classified as a major interaction, and co-administration is generally restricted or avoided.
Antidiabetic Agents Hystrogest may cause a decrease in glucose tolerance, which can require a dosage adjustment of antidiabetic agents, including Insulin and oral hypoglycemic drugs, in patients with pre-existing or latent diabetes.

Combinations classified as major interactions should typically be avoided. For moderate or minor interactions, close clinical monitoring and dose adjustments of the interacting medicine may be required to maintain safe and effective concentrations. These drug interaction statements are derived from official regulatory labeling and pharmacological studies.

Mechanism of Action

Hystrogest is a progestin, acting as an agonist at the progesterone receptor (PR), a member of the nuclear receptor superfamily of transcription factors. The drug readily crosses the cell membrane to bind the cytosolic PR, primarily the nuclear PR-A and PR-B isoforms, inducing a conformational change.

The activated PR-ligand complex dimerizes, translocates to the nucleus, and interacts with progesterone-responsive elements (PREs) within the promoters of target genes. This genomic pathway modulates the transcription of specific messenger RNA, leading to altered synthesis of downstream proteins. Downstream cascades include suppression of the hypothalamic-pituitary-gonadal axis via negative feedback on gonadotropin-releasing hormone (GnRH), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) secretion from the pituitary.

System-level physiological consequences include the transformation of the endometrium from a proliferative to a secretory state. Additionally, it modulates cervical processes by increasing cervical mucus viscosity and decreases the contractile activity of the uterine smooth muscle (myometrium) and fallopian tubes.

Dosage and Administration Information

Instruction Map: How to use Hystrogest — Administration Guidelines

This section outlines the precise procedural steps for administering Hystrogest. It provides details on the route, dosage, and specific conditions for use, without interpretation or medical advice.

Administration Scope

Guideline Instruction
Route of Administration Vaginal (via insert/tablet, using a disposable applicator).
Dosing Schedule 100 mg administered two or three times daily, as prescribed.
Timing in Relation to Meals Not applicable (Vaginal route).
Preparation Requirements Wash hands before use; the vaginal insert is single-use and requires no reconstitution or dilution.
Age-Group Administration Rules Efficacy in women 35 years of age and older has not been clearly established.
Missed-Dose Rules If a dose is missed, use it as soon as remembered. If it is almost time for the next dose, use only that dose. Do not use double or extra doses.
Special Procedural Conditions The product is not recommended for co-administration with other vaginal products (e.g., antifungal treatments) as this may alter drug release and absorption.

Instruction Classifications (High-Level)

Classification Detail
Administration Method Type Vaginal
Frequency Pattern Multiple times daily (B.I.D. or T.I.D.)
Use-Context Constraints Continued for up to 10 weeks total duration, typically starting the day after oocyte retrieval as part of an Assisted Reproductive Technology (ART) treatment program.

Resulting Procedural Structure

Step Sequence:

  • Wash hands thoroughly prior to handling the insert and applicator.
  • Unwrap the single-use applicator and tablet.
  • Position the body comfortably (e.g., lying down or squatting).
  • Guide the applicator with the tablet into the vagina.
  • Gently push the thin end of the applicator to release the tablet.
  • Administer the 100 mg dose two or three times daily, as directed by the prescribing physician.
  • Continue the daily regimen for a maximum of 10 weeks total duration.

Connection to the Overall Use Protocol (2–4 sentences): The protocol dictates a precise, self-administered vaginal route of administration for the 100 mg dose, typically occurring two or three times daily. This regimen has a maximum duration of 10 weeks and explicitly prohibits the simultaneous use of other vaginal products, thereby establishing the necessary procedural boundaries for correct use.

Recent Clinical Evidence

Recent clinical evidence underscores the established role of progestins, such as the active compound in Hystrogest (micronized progesterone), in managing various gynecological and obstetrical conditions.

Pregnancy and Preterm Birth Prevention

Clinical trials have consistently supported the use of vaginal micronized progesterone for the prevention of spontaneous preterm birth in women identified as high-risk, specifically those with a history of preterm birth or those with a short cervix detected during a mid-gestation ultrasound. The mechanism is thought to involve stabilizing the uterine muscle and maintaining uterine quiescence.

For threatened miscarriage (vaginal bleeding in early pregnancy), large randomized controlled trials (RCTs) have indicated a potential benefit of progesterone supplementation, particularly in subgroups of women with a history of recurrent miscarriage. However, routine use in all women with bleeding without a prior history of miscarriage is generally not recommended by current guidelines.

Endometrial and Other Gynecological Uses

Beyond pregnancy support, clinical data continue to support the effectiveness of progestins in the management of hormone-sensitive conditions. They are a core component of Menopausal Hormone Therapy (MHT) for women with an intact uterus, where the progestin counteracts the proliferative effect of estrogen on the endometrium, thereby reducing the risk of endometrial hyperplasia and cancer. Progestins are also utilized in the treatment of conditions like endometriosis and adenomyosis, helping to reduce associated pelvic pain and abnormal uterine bleeding by suppressing the growth of endometrial tissue.

Frequently Asked Questions (FAQ)

Common questions about Hystrogest (FAQ)

Q: What is the main difference between Hystrogest and similar progesterone medicines?

Hystrogest contains micronized progesterone, which is made to be chemically bioidentical to the progesterone hormone naturally produced by the body. This is a key distinguishing feature from other similar medicines that may use synthetic progesterone-like compounds, known as progestins, which have different chemical structures.

Q: Is Hystrogest the same as birth control?

No, Hystrogest is primarily prescribed to supplement the body's natural progesterone for conditions like hormone replacement therapy (HRT) or reproductive support. Although progesterone is a component in some birth control methods, Hystrogest is not indicated for use as a method of contraception in its current regulatory applications.

Q: Are there any common foods or supplements that interact with Hystrogest?

Official information for the oral form indicates that taking it with food can actually increase the amount of progesterone that the body absorbs. For the vaginal insert form, there are typically no specific common foods listed as restricted. Questions regarding specific supplements are typically addressed in the detailed official labeling.

Q: Can men or non-pregnant individuals use Hystrogest for other conditions?

The official applications and clinical studies for this medication focus on conditions specific to women, such as reproductive support, managing menstrual cycles, and endometrial protection. The available official documentation primarily details its use in female populations for reproductive health and hormonal balance.

Q: Does Hystrogest cause mood swings or affect mental health?

Regulatory documents state that mood swings, irritability, excessive worrying, and depression are listed as potential side effects. The official product information notes that patients with a history of depression are in a population segment for which careful monitoring is indicated.

Q: Is Hystrogest generally considered safe to use with long-term heart medications?

Official safety warnings indicate the drug should be used with caution if a person has certain pre-existing conditions like hypertension (high blood pressure) or existing cardiac dysfunction due to the risk of fluid retention. It is also strictly contraindicated if a person has a history of blood clots. Official patient information does not contain a comprehensive summary of interactions covering all specific classes of heart medications.

Q: Does Hystrogest interact with herbal supplements like St. John's Wort?

The metabolism of progesterone is strongly influenced by certain enzymes in the liver, specifically CYP450 3A4. Supplements known to increase the activity of this enzyme, such as St. John’s Wort, could potentially decrease the level of Hystrogest in the body and reduce its effect. Regulatory knowledge regarding similar enzyme-inducing substances suggests this type of pharmacokinetic interaction is possible.

Q: What is the function of the inactive ingredients in Hystrogest?

Inactive ingredients are used to stabilize the product and help ensure the active ingredient is delivered correctly. For example, in some vaginal insert forms, these ingredients can create an effervescent reaction (like bubbling) to help the tablet dissolve quickly and aid in absorption.

Q: Are there any known severe allergic reactions associated with Hystrogest?

Regulatory documents list hypersensitivity (an allergic response) as a contraindication, meaning the drug should not be used if you are allergic to it. Symptoms like hives, a spreading rash, or swelling of the face, throat, or limbs are examples of severe reactions cited in patient information.

Q: What if I take Hystrogest and then forget I took it and take it again?

Official guidance explicitly states not to use double or extra doses. Overexposure to progesterone has been associated in studies of the oral form with temporary side effects such as dizziness, lightheadedness, and profound drowsiness (somnolence). Adhering to the regimen as prescribed is important for maintaining the intended hormonal balance.

Q: Is it normal to feel tired after starting Hystrogest?

Yes, tiredness, often referred to as somnolence or drowsiness, is listed as a very common to common adverse reaction in regulatory documents for progesterone. In some clinical studies (for oral forms), this effect was reported in a significant number of women.

Q: Is it okay to drink alcohol while taking Hystrogest?

Official documentation indicates that alcohol is a potential interaction with progesterone. The potential use of alcohol while on this medication is typically a subject of discussion with a prescribing healthcare provider.

Q: Does Hystrogest affect the results of any common lab tests?

Official warnings indicate that patients require monitoring for decreased glucose tolerance, which would affect blood sugar readings. The medicine is also known to affect the results of certain hormone tests, such as those measuring levels of estrone and equilin, particularly when co-administered with estrogen.

Q: How quickly does Hystrogest leave the body after you stop taking it?

Pharmacological information states that progesterone is primarily metabolized (broken down) in the liver and then eliminated mostly by the kidneys. For the oral form, the half-life (the time it takes for half of the drug to be eliminated) is relatively short, with maximum levels typically peaking in the blood within three hours.

Q: Is there a generic version of Hystrogest available?

Yes, Hystrogest is the brand name for the active ingredient micronized progesterone. This active ingredient is available in generic forms from numerous manufacturers and is widely prescribed.

Q: Is it true that Hystrogest can help with sleep?

Official safety data confirms that a common side effect of progesterone is somnolence or drowsiness. This central nervous system effect may be experienced as a sedative property.

Q: What are the reasons someone might need to switch from Hystrogest to another medicine?

The need to switch is generally due to the development of an active contraindication, such as a new blood clot or active liver disease, which makes continued use unsafe. Another reason is the occurrence of a severe or unacceptable adverse reaction that requires the drug to be stopped.

Q: Why are there different strengths or doses available for Hystrogest?

Different strengths and dosage forms are made available to allow doctors the flexibility to optimize treatment for different conditions. For example, the dose required for endometrial protection during hormone replacement therapy is often different from the dose required for use in secondary amenorrhea.

How should Hystrogest be stored and disposed of?

The official regulatory labeling for Progesterone (the active ingredient in Hystrogest) defines strict storage and disposal requirements to ensure product integrity and safety.

Official Storage Conditions

Condition Regulatory Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F).
Environment Protect from light and excessive moisture (not in the bathroom).
Handling Do not refrigerate or freeze the medicine.
Packaging Keep in the original container, tightly closed.

Official Disposal Instructions

Unused or expired product should be disposed of via community drug take-back programs or according to local regulations. Used injection materials (sharps) must be immediately placed in an FDA-cleared sharps disposal container and should not be placed in household trash. The product must always be stored out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hystrogest found in:

A-Z Index: